The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
B-Cell Maturation Antigen (BCMA) Targeted Therapies-Global Market Insights and Sales Trends 2025
Synopsis
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of B-Cell Maturation Antigen (BCMA) Targeted Therapies in various end use industries. The expanding demands from the Liver Cancer, Respiratory Cancer, Brain Cancer and Others, are propelling B-Cell Maturation Antigen (BCMA) Targeted Therapies market. Bispecific Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antibody Drug Conjugates segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, B-Cell Maturation Antigen (BCMA) Targeted Therapies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of B-Cell Maturation Antigen (BCMA) Targeted Therapies covered in this report include Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute and Deerfield Partners, etc.
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, Segment by Type:
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of B-Cell Maturation Antigen (BCMA) Targeted Therapies in various end use industries. The expanding demands from the Liver Cancer, Respiratory Cancer, Brain Cancer and Others, are propelling B-Cell Maturation Antigen (BCMA) Targeted Therapies market. Bispecific Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Antibody Drug Conjugates segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, B-Cell Maturation Antigen (BCMA) Targeted Therapies sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of B-Cell Maturation Antigen (BCMA) Targeted Therapies covered in this report include Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, firstVentury Equity, Five Prime Therapeutics, Credit Suisse Securities, Dana-Farber Cancer Institute and Deerfield Partners, etc.
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, Segment by Type:
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of B-Cell Maturation Antigen (BCMA) Targeted Therapies
1.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview
1.1.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Scope
1.1.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Status and Outlook
1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2018-2029)
1.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Region (2018-2023)
1.5 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Forecast by Region (2024-2029)
1.6 Key Regions, B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
1.6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
1.6.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
1.6.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
1.6.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
1.6.5 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2018-2029)
2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Type
2.1 Introduction
2.1.1 Bispecific Antibodies
2.1.2 Antibody Drug Conjugates
2.1.3 Chimeric Antigen Receptor T-Cells
2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Type (2018-2023)
2.2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Type (2018-2029)
2.3.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Type (2018-2029)
3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Overview by Application
3.1 Introduction
3.1.1 Liver Cancer
3.1.2 Respiratory Cancer
3.1.3 Brain Cancer
3.1.4 Others
3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Application (2018-2023)
3.2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Application (2018-2029)
3.3.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Breakdown by Application (2018-2029)
4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Competition Analysis by Players
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies as of 2022)
4.3 Date of Key Players Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
4.4 Global Top Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Headquarters and Area Served
4.5 Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
4.6 Competitive Status
4.6.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Transposagen Biopharmaceuticals
5.1.1 Transposagen Biopharmaceuticals Profile
5.1.2 Transposagen Biopharmaceuticals Main Business
5.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.1.5 Transposagen Biopharmaceuticals Recent Developments
5.2 Sutro Biopharma
5.2.1 Sutro Biopharma Profile
5.2.2 Sutro Biopharma Main Business
5.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.2.4 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.2.5 Sutro Biopharma Recent Developments
5.3 Malin Corporation
5.3.1 Malin Corporation Profile
5.3.2 Malin Corporation Main Business
5.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.3.4 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.3.5 Eureka Therapeutics Recent Developments
5.4 Eureka Therapeutics
5.4.1 Eureka Therapeutics Profile
5.4.2 Eureka Therapeutics Main Business
5.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.4.4 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.4.5 Eureka Therapeutics Recent Developments
5.5 firstVentury Equity
5.5.1 firstVentury Equity Profile
5.5.2 firstVentury Equity Main Business
5.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.5.4 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.5.5 firstVentury Equity Recent Developments
5.6 Five Prime Therapeutics
5.6.1 Five Prime Therapeutics Profile
5.6.2 Five Prime Therapeutics Main Business
5.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.6.4 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.6.5 Five Prime Therapeutics Recent Developments
5.7 Credit Suisse Securities
5.7.1 Credit Suisse Securities Profile
5.7.2 Credit Suisse Securities Main Business
5.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.7.4 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.7.5 Credit Suisse Securities Recent Developments
5.8 Dana-Farber Cancer Institute
5.8.1 Dana-Farber Cancer Institute Profile
5.8.2 Dana-Farber Cancer Institute Main Business
5.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.8.5 Dana-Farber Cancer Institute Recent Developments
5.9 Deerfield Partners
5.9.1 Deerfield Partners Profile
5.9.2 Deerfield Partners Main Business
5.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.9.4 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.9.5 Deerfield Partners Recent Developments
5.10 Onyx Pharmaceuticals
5.10.1 Onyx Pharmaceuticals Profile
5.10.2 Onyx Pharmaceuticals Main Business
5.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.10.5 Onyx Pharmaceuticals Recent Developments
5.11 Juno Therapeutics
5.11.1 Juno Therapeutics Profile
5.11.2 Juno Therapeutics Main Business
5.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Products, Services and Solutions
5.11.4 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (US$ Million) & (2018-2023)
5.11.5 Juno Therapeutics Recent Developments
6 North America
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics
11.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends
11.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
11.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
11.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
